Overview

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-08-20

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Phase:

PHASE3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Ustekinumab